Early prolonged neutrophil activation in critically ill patients with sepsis

Sanna Törnblom1, Sara Nisula1, Suvi T Vaara1, Meri Poukkonen2, Sture Andersson3, Ville Pettila1 and Eero Pesonen4

Abstract
We hypothesised that plasma concentrations of biomarkers of neutrophil activation and pro-inflammatory cytokines differ according to the phase of rapidly evolving sepsis. In an observational study, we measured heparin-binding protein (HBP), myeloperoxidase (MPO), IL-6 and IL-8 in 167 sepsis patients on intensive care unit admission. We prospectively used the emergence of the first sepsis-associated organ dysfunction (OD) as a surrogate for the sepsis phase. Fifty-five patients (of 167, 33%) developed the first OD > 1 h before, 74 (44%) within /C6 1 h, and 38 (23%) > 1 h after intensive care unit admission. HBP and MPO were elevated at a median of 12 h before the first OD, remained high up to 24 h, and were not associated with sepsis phase. IL-6 and IL-8 rose and declined rapidly close to OD emergence. Elevation of neutrophil activation markers HBP and MPO was an early event in the evolution of sepsis, lasting beyond the subsidence of the pro-inflammatory cytokine reaction. Thus, as sepsis biomarkers, HBP and MPO were not as prone as IL-6 and IL-8 to the effect of sample timing.

Keywords
Heparin binding protein, interleukin 6, interleukin 8, myeloperoxidase, sepsis

Date received: 6 December 2019; revised: 11 November 2020; accepted: 18 November 2020

Introduction
Incidence of sepsis, a life-threatening organ dysfunction (OD) caused by a dys-regulated host response to infection,1 is increasing.2,3 Current evidence suggests that sepsis-associated OD, such as acute kidney injury (AKI), is predominantly associated with inflammation, not ischaemia/hypotension of the organ.4 Prompt recognition of sepsis, leading to earlier administration of antibiotics and start of supportive therapies, has improved survival.5 However, interventions targeting inflammation have failed.6

Sepsis develops when the immune system fails to restrict the infection at the local site. The outbreak of bacteraemia leads to activation of TLRs and systemic inflammation.7 In addition, circulating neutrophils are activated.8 In experimental sepsis, systemic activation of neutrophils results in their impaired migration to the site of infection due to down-regulated surface expression of the chemokine receptor CXCR2. Up-regulation of CC receptor expression, however, mediates infiltration of neutrophils in the lungs, kidneys and heart.7 These changes in expression of neutrophil chemokine receptors have been observed in septic patients.7 Taken together, systemic neutrophil activation is harmful for the septic patient by two means: it reduces clearance of...
bacteria at the site of infection and paradoxically increases the risk of neutrophil-mediated OD.\textsuperscript{7,8}

Heparin-binding protein (HBP) is a 37-kD granule protein of neutrophils.\textsuperscript{9} As a sensitive indicator of intravascular neutrophil activation, HBP has gained increasing interest as a promising inflammatory biomarker in severe sepsis and septic shock.\textsuperscript{10} Among septic patients, it predicts development of circulatory failure,\textsuperscript{11} respiratory failure,\textsuperscript{12} AKI\textsuperscript{13,14} and OD in general.\textsuperscript{15} Myeloperoxidase (MPO), a traditional neutrophil activation marker, is released from the azurophilic granules of neutrophils.\textsuperscript{16} Plasma MPO concentrations have been shown to correlate inversely with neutrophil CXCR2 expression.\textsuperscript{17} We have recently shown the association of urinary MPO with septic AKI.\textsuperscript{18} IL-6 is a pleiotropic cytokine possessing both pro- and anti-inflammatory properties,\textsuperscript{19} whereas IL-8 is a neutrophil chemotactic factor,\textsuperscript{20,21} which primes neutrophils in septic patients.\textsuperscript{22} Both these pro-inflammatory cytokines have been associated with AKI,\textsuperscript{23–25} disease severity and mortality.\textsuperscript{23–26}

Investigation of the kinetics of the inflammatory reaction in sepsis is difficult because patients typically present with intense inflammation on hospital admission. Here we studied the kinetics of systemic neutrophil activation (HBP and MPO) and pro-inflammatory reaction (IL-6 and IL-8) in early sepsis in critically ill patients, using the emergence of the first sepsis-associated OD as a surrogate for the sepsis phase. We hypothesised that baseline plasma levels and kinetics of IL-6, IL-8, HBP and MPO differ depending on the phase of sepsis.

Materials and methods

Patients

We investigated the kinetics of plasma HBP, MPO, IL-6 and IL-8 in the early phase of sepsis in a previously described subgroup of adult patients\textsuperscript{18} originating from the prospective nationwide FINNAKI study.\textsuperscript{27} Plasma concentrations of MPO, IL-6 and IL-8 have been previously related to development of AKI.\textsuperscript{18} We screened 237 consecutive sepsis patients (Flow chart in Figure 1) manifesting their first OD between 24 h preceding admission and the second calendar day in the intensive care unit (ICU) (that is, by 48 h following admission). Sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) criteria.\textsuperscript{28} To be included in the study, the patient had to have an infection or a strong suspicion of infection, systemic inflammatory response syndrome, and at least one OD due to infection. This definition corresponds closely to the later Sepsis 3.0 criteria for sepsis.\textsuperscript{1} The screened OD comprised acute respiratory, cardiovascular, acute kidney and liver dysfunctions, hypotension despite adequate fluid resuscitation, metabolic acidosis, disseminated intravascular coagulation, and hypoperfusion (lactatemia, oliguria or decreased level of consciousness). We excluded patients with chronic kidney disease (glomerular filtration rate less than 60 ml/min/1.73 m\textsuperscript{2}), those without both admission and 24 h plasma samples available, and those without a recorded time label for the first sepsis-associated OD.

Figure 1. Flow chart of the study cohort.
The final number of included patients was 167 (Figure 1, Table 1). In addition, we assayed HBP, MPO, IL-6 and IL-8 in 20 healthy adult controls.

The local ethics committee approved the FINNAKI study (18/13/03/02/2010), from which the study cohort was derived, with use of a deferred consent, as well as recruitment of the control cohort (HUS/606/2020). We obtained a written informed consent from each patient or his/her proxy and from each volunteer of the control cohort.

Clinical data and onset of sepsis
We prospectively collected clinical data using a standardised case report form (CRF) filled on admission and daily thereafter by the responsible clinician. The CRF data included screening for sepsis and sepsis-associated OD 24 h preceding admission, on ICU admission day, and each day thereafter until discharge or d 5 in the ICU. The clinicians documented the starting date and time (hh:mm) for each emerging OD when any of the following pre-defined criteria were met:

- Hypotension: systolic arterial pressure (SAP) ≥90 mmHg, or reduction of over 40 mmHg from baseline, or inotrope/vasopressor treatment.
- Hypoperfusion: lactate above the reference value, or oliguria, or acutely altered mental status.
- Acute respiratory dysfunction: PaO₂/FiO₂ ratio <200 mm Hg, if respiratory dysfunction only, and <250 mm Hg, if other ODs present.
- Acute kidney dysfunction: urine output ≤0.5 ml/kg for one h despite adequate fluid resuscitation.
- Acute cardiovascular dysfunction: SAP ≥ 90 mm Hg or mean arterial pressure (MAP) ≤ 70 mm Hg for at least an h.
- Acute haematological dysfunction: thrombocytes ≤80 E9/l or ≥50% decrease in 3 d.
- Unexplained metabolic acidosis: pH ≤ 7.30, or base excess (BE) ≤-5 and lactate >1.5 times normal likely to be caused by infection.

We collected physiological data including Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA) scores of the first 5 d of ICU stay from the quality database of the Finnish Intensive Care Consortium maintained by Tieto Ltd, Helsinki, Finland.

Blood samples
Blood samples were obtained in ethylenediaminetetraacetic acid tubes on ICU admission. In the subgroup with the first OD close to admission (sample 'at OD', see Statistical analysis section), blood samples taken 24 h after admission were also analysed. The tubes were centrifuged and aliquoted immediately after ICU admission or at 2 h at the latest and stored at –80°C until assayed. Including aliquoting and analyses, the samples were thawed a maximum of three times. Control samples were collected in the same way. To

| Table 1. Baseline characteristics of critically ill sepsis patients (n = 167). |
|---------------------------------|------------------|-----------------|
| Age, median [IQR]              | 62 [53 – 72]     | 167             |
| Male gender, n (%)             | 108 (65)         | 167             |
| Comorbidities, n (%)           | Hypertension     | 77 (47)         |
|                                | Insulin or oral medication for diabetes | 34 (20) |
|                                | Atherosclerosis  | 17 (10)         |
|                                | Systolic heart failure | 12 (7) |
| Admission type and status      | Emergency, n (%) | 164 (98)        |
|                                | Operative, n (%) | 36 (22)         |
|                                | SAPS II, median [IQR] | 43 [35 – 52] |
|                                | APACHE II, median [IQR] | 23 [19–29] |
| Severity of disease and organ dysfunction | Septic shock in first 5 ICU days, n (%) | 118 (71) |
|                                | Lactate, mmol/l (first in ICU, median [IQR]) | 1.6 [1.0–3.5] |
|                                | SOFA < 24 h, median [IQR] | 8 [6–11] |
|                                | Highest SOFA, median [IQR] | 10 [7–12] |
|                                | AKI, n (%)       | 85 (51)         |
|                                | RRT for AKI, n (%) | 23 (14) |
| ICU LOS, days, median [IQR]    | 4.5 [2.7–8.1]   | 167             |

Data expressed as median [IQR] or count (%). IQR: interquartile range; SAPS: Simplified Acute Physiology Score; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; AKI: acute kidney injury; RRT: renal replacement therapy; ICU: intensive care unit; LOS: length of stay.
analyse both study and control samples we used commercial ELISA kits for IL-6 (DiaClone, Besancon, France; detection limit 2 pg/ml), IL-8 (Cymax, Abfrontier, Seoul, South-Korea; detection limit 0.3 pg/ml), HBP (Axis-Shiled Diagnostics, Dundee, UK; detection limit 5.9 ng/ml) and MPO (BioLegend Inc., San Diego, CA, USA; detection limit 28 pg/ml) analyses. The researchers conducting the analyses were blinded to the subgrouping (see Statistical analysis section) of the study patients.

**Statistical analysis**

We divided the patients into three groups based on the time of the first OD in relation to ICU admission. We used cut-off points of 1 h before and after admission. Because blood samples were taken at the time of ICU admission, the groups were named according to the time of blood sampling in relation to OD: sample ‘before OD’ (the first OD over 1 h after admission), ‘at OD’ (the first OD ± 1 h from admission) and ‘after OD’ (the first OD over 1 h before admission; Table 2).

As relevant publications for calculation of statistical power did not exist, we used the results of an unpublished pilot cohort of 32 sepsis patients to conduct the power analysis for the study. Because sample size cannot be calculated for a non-parametric test, we based sample size estimation on a one-way ANOVA, which is equivalent to the Kruskal–Wallis test. To gain the sample size for a non-parametric test, we added 10% to the number of patients, as suggested. The eta-square for IL-6 was 0.316 and for IL-8 0.360. The minimum group size for the one-way ANOVA was 33 patients for IL-6 and 26 patients for IL-8 (α = 0.05, 1-β = 0.80). Consequently, the minimum patient number for Kruskal–Wallis test would have been 37 patients. For HBP and MPO, power analysis was not applicable because there were no differences in their levels between the time points in the pilot cohort.

As HBP, MPO, IL-6 and IL-8 plasma concentrations were not normally distributed, non-parametric tests (Friedman, Kruskal–Wallis, Mann–Whitney and Wilcoxon tests) were used, as appropriate. Proportions were compared with chi-square or Fisher’s exact test.

**Table 2. Characteristics of the three groups with different sampling time in relation to emergence of organ dysfunction.**

| Time from ICU admission to first documented OD, h, median (range) | Data available | Before OD (n = 38) | At OD (n = 74) | After OD (n = 55) | p |
|---|---|---|---|---|---|
| Age, median [IQR] | 167 | 60 [50–71] | 63 [56–73] | 61 [52–72] | 0.310 |
| Male gender, n (%) | 167 | 24 (63) | 46 (62) | 38 (69) | 0.700 |
| Comorbidities, n (%) | | | | | |
| Hypertension | 165 | 15 (40) | 31 (42) | 31 (56) | 0.238 |
| Diabetes with oral or insulin medication | 165 | 8 (21) | 12 (16) | 14 (26) | 0.433 |
| Atherosclerosis | 165 | 4 (11) | 7 (10) | 6 (11) | 0.853 |
| Systolic heart failure | 165 | 3 (8) | 7 (10) | 2 (4) | 0.451 |
| Admission type and status | | | | | |
| Emergency, n (%) | 167 | 38 (100) | 72 (97) | 54 (98) | 0.797 |
| Operative, n (%) | 166 | 13 (34) | 6 (8) | 17 (31) | 0.001 |
| SAPS II, median [IQR] | 167 | 41 [32–51] | 44 [35–56] | 44 [36–50] | 0.459 |
| APACHE II, median [IQR] | 167 | 23 [18–29] | 24 [19–30] | 23 [20–29] | 0.510 |

Sepsis severity and organ dysfunction

| Data available | Before OD (n = 38) | At OD (n = 74) | After OD (n = 55) | p |
|---|---|---|---|---|
| Septic shock (first 5 ICU days, n (%)) | 167 | 26 (68) | 49 (66) | 43 (78) | 0.317 |
| Lactate, mmol/l (first in ICU, median [IQR]) | 134 | 1.5 [1.1–2.1] | 1.6 [1.0–3.7] | 1.6 [1.0–4.0] | 0.612 |
| Highest SOFA, median [IQR] | 167 | 9 [8–12] | 9 [7–11] | 10 [7–12] | 0.342 |
| Respiratory SOFA ≥ 2, n (%) | 167 | 34 (90) | 65 (88) | 53 (96) | 0.208 |
| CNS SOFA ≥ 2, n (%) | 153 | 19 (50) | 37/70 (53) | 21/45 (47) | 0.810 |
| Coagulation SOFA ≥ 2, n (%) | 167 | 13 (34) | 21 (28) | 19 (35) | 0.707 |
| Liver SOFA ≥ 2, n (%) | 158 | 9/36 (25) | 11/70 (16) | 12/52 (23) | 0.438 |
| AKI, n (%) | 167 | 19 (50) | 34 (46) | 32 (58) | 0.386 |
| RRT for AKI, n (%) | 167 | 4 (11) | 10 (14) | 9 (16) | 0.722 |
| ICU LOS, d, median [IQR] | 167 | 4.6 [2.9–8.3] | 4.1 [2.6–8.0] | 5.0 [2.7–8.2] | 0.856 |

*Before OD*: patients who developed their first organ dysfunction > 1 h after ICU admission; *At OD*: patients presenting their first organ dysfunction ± 1 h from admission; *After OD*: patients who had organ dysfunction > 1 h before ICU admission. *A* negative value indicates that organ dysfunction has emerged before admission. ICU: intensive care unit; IQR: interquartile range; SAPS: Simplified Acute Physiology Score; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CNS: central nervous system; AKI: acute kidney injury; RRT: renal replacement therapy; LOS: length of stay.
and bivariate correlations with the non-parametric Spearman test. A pairwise comparison was used as a post hoc test for the Kruskal–Wallis test. A $P$ value $<0.05$ was considered significant. The data are expressed as numbers and percentages, as median with interquartile range (IQR) or range (data involving time), or depicted as box plots with median, IQR and range. Statistical analyses were conducted using SPSS 22 software (SPSS Inc., Chicago, IL, USA).

**Results**

The baseline characteristics of the patients ($n=167$) are presented in Table 1. The median time between ICU admission and the emergence of the first OD was 0.0 h, ranging from 23.8 h before admission to 45.6 h after admission. Of 167 patients, 38 (23%) developed their first OD later than 1 h after admission (blood sampling ‘before OD’), 74 (44%) within an interval of $\pm1$ h from admission (blood sampling ‘at OD’), and 55 (33%) presented with the first documented OD earlier than 1 h before admission (blood sampling ‘after OD’; Figure 1, Table 2). The baseline characteristics of these three groups are shown in Table 2. The groups were comparable regarding comorbidities, disease severity and presence of different ODs (Table 2).

We analysed IL-6 and MPO of all 167 patients. Due to an insufficient amount of plasma, we could not analyse IL-8 of two patients and HBP of four patients. All four biomarkers of the 20 healthy controls with median age 34 [3142] yr, 8 (40%) males and 12 (60%) females were analysed. Among 167 sepsis patients, there was a strong positive correlation between HBP and MPO ($r=0.737$, $P<0.001$) as well as between IL-6 and IL-8 ($r=0.811$, $P<0.001$) on admission. Positive correlations were also observed between neutrophil activation markers (MPO and HBP) and IL-6 and -8 with correlation coefficients ranging from 0.309 to 0.477 ($P<0.001$ for all). The concentrations of the biomarkers in controls and in the three patient groups with different onset of OD compared with blood sampling time are presented in Figure 2. Healthy controls had lower concentrations than sepsis patients in all studied biomarkers (Figure 2). Plasma HBP or MPO concentrations did not differ between the three groups, but levels of IL-6 ($P<0.01$) and IL-8 ($P<0.05$) increased close to the onset of the first OD (Figures 2 and 3). Figure 3 illustrates the concentrations of the biomarkers relative to OD.

Among patients with the first OD $\pm1$ h from admission (subgroup with sample ‘at OD’, $n=74$), we compared the plasma concentrations measured 24 h after ICU admission with the concentrations on admission (Figure 4). A statistically significant decline between 0

---

**Figure 2.** Inflammatory biomarkers a) HBP, b) MPO, c) IL-6, and d) IL-8 in controls and in the three groups with different sampling time in relation to the onset of organ dysfunction (‘before OD’, ‘at OD’ and ‘after OD’). *$P<0.01$, controls vs. before OD/at OD/after OD; **$P<0.05$, among sepsis patients; ***$P<0.01$, among sepsis patients.
Figure 3. Concentrations of inflammatory biomarkers a) HBP, b) MPO, c) IL-6, and d) IL-8 in relation to emergence of organ dysfunction (OD). Negative values on x-axis indicate h before first OD and positive values indicate h after first OD.

Figure 4. Inflammatory biomarkers a) HBP, b) MPO, c) IL-6, and d) IL-8 in the subgroup of patients with onset of organ dysfunction ± 1 h from ICU admission at 0 h (admission) and 24 h later (24 h; n = 74). ***p < 0.001
and 24 h was observed in IL-6 and IL-8, but not in HBP or MPO.

**Discussion**

In this study comprising adult critically ill septic patients we found that intravascular neutrophil activation measured by plasma HBP and MPO concentrations had steadily elevated before the onset of sepsis and remained elevated up to 24 h. Unexpectedly, systemic neutrophil activation did not follow the kinetics of pro-inflammatory cytokines: the rise and fall of plasma IL-6 and IL-8 concentrations followed rapid kinetics close to the onset of the first OD.

**Neutrophil activation**

In this study, prospectively documented emergence of the first sepsis-associated OD was used as a surrogate for the sepsis phase. In the subgroup ‘before OD’, median plasma HBP was 23.7 ng/ml and median plasma MPO 130.2 ng/ml at a median of 12 h before the first OD, whereas healthy controls had a median HBP concentration of 10.6 ng/ml and MPO concentration of 56 ng/ml. In other words, plasma concentrations of neutrophil activation biomarkers HBP and MPO were markedly increased early in the course of sepsis. In agreement, increased plasma HBP concentrations have been detected in sepsis up to 12 h before circulatory failure and up to 24 h before OD. Furthermore, neutrophil activation was not limited to the emergence of sepsis. Corroborating findings in HBP, neutrophil activation (by HBP and MPO) lasted at least for the first 24 h following the emergence of the first OD.

**Interplay between neutrophil activation and pro-inflammatory cytokines**

The kinetics of the pro-inflammatory cytokines differed distinctly from the neutrophil activation markers. The present results suggest that the increase of IL-6 and IL-8 occurs within hours. The rise of the pro-inflammatory cytokines was sharp around the onset of the first OD. In experimental endotoxemia in healthy volunteers, IL-6 and IL-8 concentrations increased steeply within 1 to 2 h, resembling our findings. In a murine model of caecal ligation and puncture, IL-6 and IL-8 increased more steadily and peaked at 16 h. We detected higher plasma IL-6 and IL-8 concentrations in the subgroup of patients presenting with the first OD median of 4 h before ICU admission than in patients with onset of OD on ICU admission. However, the latter patients showed lower pro-inflammatory cytokine concentrations at 24 h after ICU admission than at the time of admission. These results suggest that the peak of IL-6 and IL-8 occurred at some point during the first 24 h after evolution of the first OD. The decline of the pro-inflammatory cytokines seems to occur rapidly as well. Assessed among the subgroup with sampling ‘at OD’, the pro-inflammatory cytokines decreased profoundly during the first 24 h following the first OD. Our results are consistent with three previous clinical studies in severe sepsis.

Pro-inflammatory cytokines probably do not have cytotoxic effects by themselves. Instead, they are mediators and regulators of pathophysiological processes. IL-8 is an important endogenous chemotactic factor of neutrophils and primes neutrophils in septic patients. Nevertheless, according to the present results, circulating IL-8 does not seem to be linked to intravascular neutrophil activation in septic patients. It should be noted, however, that we measured inflammation at the systemic level. Indeed, local cytokine concentrations at the site of infection and at organ level may be different. Furthermore, it has been suggested that microbiological agents may directly activate neutrophils resulting in elevated plasma HBP concentrations.

**Clinical implications**

As for the clinical implications of the present results there are two aspects to consider. First, neutrophil activation can be detected for hours before emergence of OD. Although it is practically impossible to modify excessive neutrophil activation in a safe way, the consequences of it might be alleviated. As an example, heparin reduces HBP-mediated endothelial hyperpermeability in experimental conditions. If this kind of intervention has clinical significance, such treatment should be started as early as possible on patient admission to the hospital rather than waiting until ICU admission.

Second, from the biomarker point of view, HBP and MPO remained stably elevated between consecutive time points. In contrast, a difference of only a few hours in sample timing may have a significant effect in the obtained IL-6 and IL-8 concentrations. Obviously, neutrophil activation markers are not as prone as pro-inflammatory cytokines to the effect of sample timing, and HBP has been suggested to be superior to IL-6 as a biomarker of sepsis. In a recent study, sepsis phenotypes were distinguished by inflammatory biomarkers, which were highest among the phenotypes with the highest mortality. As an early and relatively stable inflammatory biomarker, HBP may help to recognise high-risk sepsis patients.
Limitations and strengths

Our study has some limitations and strengths. First, a key question is whether the post hoc grouping of the patients according to the emergence of the first OD in relation to admission and sampling carries confounding factors influencing the interpretation of the results. This does not seem to be the case as the three groups were comparable in terms of comorbidities as well as ODs and disease severity. Second, the recorded time for the first OD is not always accurate in patients who develop OD before ICU admission. OD, although present, might not be monitored and diagnosed until in the ICU. Third, we did not study neutrophil function directly (e.g. phagocytosis, oxidative burst or receptor expression). Fourth, at the enrollment of the study cohorts the new Sepsis 3.0 definition did not exist.1 However, we checked post hoc whether the patients fulfilled the Sepsis 3.0 criteria. Only one patient had a SOFA score change < 2 during the first 24 h in ICU. Therefore, we used the term sepsis instead of severe sepsis. The main strength of our study is the prospective documentation of the onset of the first OD. Furthermore, we used two parallel biomarkers for detection of both neutrophil activation (HBP and MPO) and pro-inflammatory reaction (IL-6 and IL-8) to confirm our findings.

Conclusion

We found that systemic neutrophil activation, measured by HBP and MPO, occurs early and lasts for at least 24 h in the evolution of sepsis. This contrasts the rapid changes in IL-6 and IL-8 concentrations close to the onset of the first OD. Implications of ongoing neutrophil activation on sepsis pathophysiology and performance of neutrophil granule proteins as sepsis biomarkers need to be further addressed.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclose receipt of the following financial support for the research, authorship, and/or publication of this article: Sigrid Juselius Foundation, Päiviikki and Sakari Sohlberg Foundation, and Special Governmental Subsidy for Health Sciences (TYH2013343, TYH2016243).

ORCID iD

Sanna Törnblom https://orcid.org/0000-0003-0534-9204

References

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315: 801–810.
2. Lagu T, Rothenberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. *Crit Care Med* 2012; 40: 754–761.
3. Poukkonen M, Vaara ST, Pettilä V, et al.; FINNAKI Study Group. Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units. *Acta Anaesthesiol Scand* 2013; 57: 863–872.
4. Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, micro-circulatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. *Shock* 2014; 41: 3–11.
5. Stevenson EK, Rubenstein AR, Radin GT, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. *Crit Care Med* 2014; 42: 625–631.
6. Angus DC. The search for effective therapy for sepsis: back to the drawing board? *JAMA* 2011; 306: 2614–2615.
7. Sønega F, Castanheira FV, Ferreira RG, et al. Paradoxical roles of the neutrophil in sepsis: protective and deleterious. *Front Immunol* 2016; 7: 155.
8. Navarini AA, Lang KS, Verschoor A, et al. Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. *Proc Nail Acad Sci USA* 2009; 106: 7107–7112.
9. Fisher J and Linder A. Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis. *J Intern Med* 2017; 281: 562–574.
10. Linder A, Åkesson P, Inghammar M, et al. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. *Crit Care* 2012; 16: R90.
11. Linder A, Christensson B, Herwald H, et al. Heparin-binding protein: an early marker of circulatory failure in sepsis. *Clin Infect Dis* 2009; 49: 1044–1050.
12. Lin Q, Shen J, Shen L, et al. Increased plasma levels of heparin-binding protein in patients with acute respiratory distress syndrome. *Crit Care* 2013; 17: R155.
13. Fisher J, Russell JA, Bentzer P, et al. Heparin-binding protein (HBP): a causative marker and potential target for heparin treatment of human sepsis-induced acute kidney injury. *Shock* 2017; 48: 313–320.
14. Tverring J, Vaara ST, Fisher J, et al.; FINNAKI Study Group. Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury. *Ann Intensive Care* 2017; 7: 105.
15. Linder A, Arnold R, Boyd JH, et al. Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. *Crit Care Med* 2015; 43: 2378–2386.
16. Tapper H, Karlsson A, Mőrgelin M, et al. Secretion of heparin-binding protein from human neutrophils is
determined by its localization in azurophilic granules and secretory vesicles. *Blood* 2002; 99: 1785–1793.

17. Gessler P, Pretre R, Hohl V, et al. CXC-chemokine stimulation of neutrophils correlates with plasma levels of myeloperoxidase and lactoferrin and contributes to clinical outcome after pediatric cardiac surgery. *Shock* 2004; 22: 513–520.

18. Törnblo m S, Nisula S, Vaara ST, et al. Neutrophil activation in septic acute kidney injury: a post hoc analysis of the FINNAKI study. *Acta Anaesthesiol Scand* 2019; 63: 1390–1397.

19. Song M and Kellum JA. Interleukin-6. *Crit Care Med* 2005; 33: S463–465.

20. Stillie R, Farooq SM, Gordon JR, et al. The functional significance behind expressing two IL-8 receptor types on PMN. *J Leukoc Biol* 2009; 86: 529–543.

21. Bergin DA, Reeves EP, Meleady P, et al. α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. *J Clin Invest* 2010; 120: 4236–4250.

22. Mariano F, Tetta C, Guida G, et al. Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients. *Kidney Int* 2001; 60: 1598–1605.

23. Payen D, Łukaszewicz AC, Legrand M, et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. *PLoS One* 2012; 7: e35838.

24. Chawla LS, Seneff MG, Nelson DR, et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. *Clin J Am Soc Nephrol* 2007; 2: 22–30.

25. Murugan R, Karajala-Subramanyam V, Lee M, et al; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. *Kidney Int* 2010; 77: 527–535.

26. Surbatovic M, Popovic N, Vojvodic D, et al. Cytokine profile in severe gram-positive and gram-negative abdominal sepsis. *Sci Rep* 2015; 5: 11355.

27. Nisula S, Kaukonen KM, Vaara ST, et al.; FINNAKI Study Group. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. *Intensive Care Med* 2013; 39: 420–428.

28. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992; 101: 1644–1655.

29. Fong Y, Moldawer LL, Marano M, et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. *J Immunol* 1989; 142: 2321–2324.

30. Soop A, Johansson C, Hjemdahl P, et al. Adenosine treatment attenuates cytokine interleukin-6 responses to endotoxin challenge in healthy volunteers. *Shock* 2003; 19: 503–507.

31. Ebong S, Call D, Nemzek J, et al. Immunopathologic alterations in murine models of sepsis of increasing severity. * Infect Immun* 1999; 67: 6603–6610.

32. Macdonald SP, Stone SF, Neil CL, et al. Sustained elevation of resistin, NGAL and IL-8 are associated with severe sepsis/septic shock in the emergency department. *PLoS One* 2014; 9: e10678.

33. Herwald H, Cramer H, Mörgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. *Cell* 2004; 116: 367–379.

34. Bentzer P, Fisher J, Kong HJ, et al. Heparin-binding protein is important for vascular leak in sepsis. *Intensive Care Med Exp* 2016; 4: 33.

35. Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. *JAMA* 2019; 321: 2003–2017.